ELIQUIS SPRINKLE Drug Patent Profile
✉ Email this page to a colleague
When do Eliquis Sprinkle patents expire, and what generic alternatives are available?
Eliquis Sprinkle is a drug marketed by Bristol and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in ELIQUIS SPRINKLE is apixaban. Eight suppliers are listed for this compound. Additional details are available on the apixaban profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eliquis Sprinkle
A generic version of ELIQUIS SPRINKLE was approved as apixaban by ACCORD HLTHCARE on July 28th, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ELIQUIS SPRINKLE?
- What are the global sales for ELIQUIS SPRINKLE?
- What is Average Wholesale Price for ELIQUIS SPRINKLE?
Summary for ELIQUIS SPRINKLE
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ELIQUIS SPRINKLE |
US Patents and Regulatory Information for ELIQUIS SPRINKLE
ELIQUIS SPRINKLE is protected by two US patents and two FDA Regulatory Exclusivities.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | ELIQUIS SPRINKLE | apixaban | FOR SUSPENSION;ORAL | 220073-001 | Apr 17, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bristol | ELIQUIS SPRINKLE | apixaban | FOR SUSPENSION;ORAL | 220073-001 | Apr 17, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol | ELIQUIS SPRINKLE | apixaban | FOR SUSPENSION;ORAL | 220073-001 | Apr 17, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bristol | ELIQUIS SPRINKLE | apixaban | FOR SUSPENSION;ORAL | 220073-001 | Apr 17, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ELIQUIS SPRINKLE
See the table below for patents covering ELIQUIS SPRINKLE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2019255599 | ⤷ Start Trial | |
| Brazil | 112020020941 | ⤷ Start Trial | |
| Canada | 3097176 | ⤷ Start Trial | |
| Denmark | 3781132 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ELIQUIS SPRINKLE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1427415 | CA 2011 00028 | Denmark | ⤷ Start Trial | |
| 1427415 | 115 5011-2011 | Slovakia | ⤷ Start Trial | OWNER(S): BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY, STEINHAUSEN, CH |
| 1427415 | 1190029-7 | Sweden | ⤷ Start Trial | PRODUCT NAME: APIXABAN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/11/691/001-005 20110518 |
| 1427415 | SPC/GB11/042 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: APIXABAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/11/691/001 20110520; UK EU/1/11/691/002 20110520; UK EU/1/11/691/003 20110520; UK EU/1/11/691/004 20110520; UK EU/1/11/691/005 20110520 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch